Associated Papers
UVI5008: the first reversible, non-covalent Bruton's tyrosine kinase epi-inhibitor for B-cell malignancies.
Dell'Aversana C et al.
Journal of Hematology & Oncology, 2026
Sub-stoichiometric Degradation is Dispensable for Potent PROTACs: A Case Study for Irreversible Covalent BTK Degraders.
Cheng R et al.
Biorxiv : the Preprint Server for Biology, 2026
Design, Synthesis, and Biological Evaluation of the First Novel Macrocycle-Based FGFR Inhibitors That Overcome Clinically Acquired Resistance.
Xiang S et al.
Journal of Medicinal Chemistry, 2026
PLCG2 across human disease: genetic variants, signaling mechanisms, and clinical implications.
Jiang P et al.
Journal of Translational Medicine, 2026
Genomic determinants of response and resistance to pirtobrutinib in relapsed/refractory chronic lymphocytic leukemia.
Brown JR et al.
Blood, 2026
Dioxazolones as Masked Isocyanate Electrophiles for Global Profiling of Lysine Reactivity and Ligandability.
Feng Y et al.
Journal of the American Chemical Society, 2025
Evaluation of the Role of AID-Induced Mutagenesis in Resistance to B-Cell Receptor Pathway Inhibitors in Chronic Lymphocytic Leukemia.
Pighi C et al.
Current Issues in Molecular Biology, 2025
Bruton Tyrosine Kinase Inhibitors in Mantle Cell Lymphoma: What Are the Current Options?
Caserta S et al.
European Journal of Haematology, 2025
Clinical Validation of a Rapid Automated Lymphoma Next-Generation Sequencing Panel.
Krigstein M et al.
Annals of Laboratory Medicine, 2025
Microsecond simulations to investigate the structural mechanism of super-resistant double mutations in BTK to the covalent inhibitor ibrutinib in multiple leukemia.
Khan A et al.
Scientific Reports, 2025
Genes-first and phenotypes-first paths to treatment resistance in hematological malignancies.
Tamellini E et al.
Cell Death & Disease, 2025
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
Pharmacological profiling in CLL patients during pirtobrutinib therapy and disease progression.
Tantawy SI et al.
Blood Cancer Journal, 2025
Discovery of degrader for FLT3, GSPT1 and IKZF1/3 proteins merging PROTAC and molecular glue targeting FLT3-ITD mutant acute myeloid leukemia.
Yang Y et al.
European Journal of Medicinal Chemistry, 2025
Resistance to CDK7 inhibitors directed by acquired mutation of a conserved residue in cancer cells.
Lai CF et al.
The Embo Journal, 2025
Exploring pocket-aware inhibitors of BTK kinase by generative deep learning, molecular docking, and molecular dynamics simulations.
Zheng LT et al.
Rsc Advances, 2025
Pirtobrutinib in Chronic Lymphocytic Leukemia: Navigating Resistance and the Personalisation of BTK-Targeted Therapy.
Molica S et al.
Cancers, 2025
Novel isolated mutations at the C515 residue of BTK in a CLL patient associated with acalabrutinib resistance.
Dimou M et al.
Leukemia & Lymphoma, 2025
Resistance to targeted therapies in chronic lymphocytic leukemia: Current status and perspectives for clinical and diagnostic practice.
Blombery P et al.
Leukemia, 2025
Heat stress targets and degrades BCR::ABL1 oncoproteins to overcome drug-resistance in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Yang C et al.
Leukemia, 2025
Telomere attrition becomes an instrument for clonal selection in aging hematopoiesis and leukemogenesis.
McLoughlin MA et al.
Nature Genetics, 2025
In Silico Investigation of BTK as a Potent Immunomodulatory Target: Exploring Novel Therapeutic Approaches for Multiple Sclerosis.
Saba A et al.
Acs Omega, 2025
Resistance mechanisms and clonal dynamics in mantle cell lymphoma treated with sequential BTKi and venetoclax therapy.
László T et al.
The Journal of Pathology, 2025
Resistance mechanisms and approach to chronic lymphocytic leukemia after BTK inhibitor therapy.
Gruessner C et al.
Leukemia & Lymphoma, 2025
Discovery of Reversible, Noncovalent Bruton's Tyrosine Kinase Inhibitors Targeting BTK C481S Mutation.
Das D et al.
Acs Medicinal Chemistry Letters, 2025
Benchmarking large language models GPT-4o, llama 3.1, and qwen 2.5 for cancer genetic variant classification.
Lin KH et al.
Npj Precision Oncology, 2025
Computational insights into mutation-induced binding changes in Bruton's Tyrosine Kinase with non-covalent inhibitors.
Mallen JJ et al.
Journal of Biomolecular Structure & Dynamics, 2025
Multiplex digital PCR enables sensitive detection of resistance to BTK inhibitors.
Garcia M et al.
Annals of Hematology, 2025
Acquired mutations in patients with relapsed/refractory CLL who progressed in the ALPINE study.
Brown JR et al.
Blood Advances, 2025
Long-read single-cell RNA sequencing enables the study of cancer subclone-specific genotypes and phenotypes in chronic lymphocytic leukemia.
Black GS et al.
Genome Research, 2025
Comprehensive Characterization of Bruton's Tyrosine Kinase Inhibitor Specificity, Potency, and Biological Effects: Insights into Covalent and Noncovalent Mechanistic Signatures.
Darragh AC et al.
Acs Pharmacology & Translational Science, 2025
Pharmacological profiling in CLL patients during pirtobrutinib therapy and disease progression.
Gandhi V et al.
Research Square, 2025
Genetic Profiling of Acute and Chronic Leukemia via Next-Generation Sequencing: Current Insights and Future Perspectives.
Pratiwi L et al.
Hematology Reports, 2025
Novel mechanisms of resistance in CLL: variant BTK mutations in second-generation and noncovalent BTK inhibitors.
Tam CS et al.
Blood, 2025
Prevalence of BTK and PLCG2 Mutations in CLL Patients With Disease Progression on BTK Inhibitor Therapy: A Meta-Analysis.
Molica S et al.
American Journal of Hematology, 2025
Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation.
Kumar A et al.
Blood, 2025
Bruton's Tyrosine Kinase (BTK) Mutations in Chronic Lymphocytic Leukemia (CLL): A Clinical View.
Molica S et al.
Mediterranean Journal of Hematology and Infectious Diseases, 2025
Combined cellular and biochemical profiling of Bruton's tyrosine kinase inhibitor nemtabrutinib reveals potential application in MAPK-driven cancers.
Kluitmans DJF et al.
Frontiers in Oncology, 2025
Impact of the clinically approved BTK inhibitors on the conformation of full-length BTK and analysis of the development of BTK resistance mutations in chronic lymphocytic leukemia.
Joseph RE et al.
Elife, 2024
Efficacy and challenges involving combination therapies in CLL.
Alanazi MA et al.
Drug Discovery Today, 2024
Emergence of IGH::CCND1 rearrangement and mutations in TP53, BTK, and BCL2 associated with therapy resistance in chronic lymphocytic leukemia.
Wei Q et al.
Ejhaem, 2024
Discovery of new non-covalent reversible BTK inhibitors: Synthesis, in silico studies, and in vitro evaluations.
Wang Z et al.
Chemico-biological Interactions, 2024